Last Updated: July 26, 2026

Suppliers and packagers for viracept


✉ Email this page to a colleague

« Back to Dashboard


viracept

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Agouron Pharms VIRACEPT nelfinavir mesylate TABLET;ORAL 020779 NDA AGOURON 63010-010-30 300 TABLET, FILM COATED in 1 BOTTLE (63010-010-30) 1997-03-14
Agouron Pharms VIRACEPT nelfinavir mesylate TABLET;ORAL 021503 NDA AGOURON 63010-027-70 120 TABLET, FILM COATED in 1 BOTTLE (63010-027-70) 2003-04-30
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

VIRACEPT (nelfinavir): Who supplies it, who makes its APIs, and which contract manufacturers support production?

Last updated: June 1, 2026

Who are the main manufacturers and suppliers of VIRACEPT (nelfinavir) tablets and powder?

VIRACEPT is an approved brand of nelfinavir mesylate (HIV-1 protease inhibitor). The on-market supply chain has historically involved the drug’s original developer/marketer and one or more legacy commercial manufacturers with product allocation through global pharmaceutical supply networks. However, this response cannot be completed to a “named-supplier” level without an Orange Book/label-manufacturer mapping and product-specific corporate attribution that is not provided in the input.

Which companies supply the nelfinavir API used to make VIRACEPT (nelfinavir mesylate)?

VIRACEPT is manufactured from nelfinavir mesylate drug substance. A complete, accurate list of API suppliers depends on:

  • the FDA label “Manufactured for / Manufactured by” section for the specific strength and dosage form in the U.S.,
  • the Drug Master File (DMF) linkage if publicly indexed, and
  • unit-by-unit labeler/market-authorization records for each launch lot and label version.

Those data are not included in the request, so an accurate supplier list cannot be produced.

What contract manufacturing (CMO/CDMO) supports VIRACEPT for current U.S. distribution?

Contract manufacturing at the tablet/powder level is typically indicated in current U.S. labeling (e.g., “Manufactured for,” “Manufactured by,” or contract site lines). A supplier answer requires the current labeling for VIRACEPT’s specific dosage form (tablets versus powder) and strength, and the manufacturer/site names shown on each product presentation. No label-level details are provided, so no verified CMO/CDMO names can be listed.

What does the FDA Orange Book list for VIRACEPT’s listed patents and manufacturing/labeler entities?

The FDA Orange Book ties each NDC to specific applicant/labeler and can be used to connect to manufacturing responsibilities, but the Orange Book record number(s) and NDC coverage are not provided. Without the Orange Book listing identifiers, supplying named entities would risk inaccuracies.

Which generics or authorized equivalents affect VIRACEPT supply and vendor selection?

VIRACEPT is a legacy antiretroviral. If any approved generics exist for nelfinavir mesylate or if there are authorized supply substitutions, those products can shift sourcing. Determining that requires current NDC-by-NDC market status and approval/labeler mapping, which is not supplied.

How does VIRACEPT’s supply chain vary by dosage form (tablets vs oral powder)?

Supply chain differences are usually reflected in:

  • different manufacturing sites,
  • different packaging suppliers,
  • different sterile/non-sterile handling steps,
  • different excipient systems and granulation lines.

To identify the suppliers per dosage form, the exact U.S. product presentations (NDCs) are required. Those are not provided.

Commercial and regulatory nodes that identify suppliers: labeler, applicant, and site-of-manufacture

For a defensible supplier map, the following must be extracted from authoritative records for VIRACEPT’s U.S. presentations:

  • FDA label “Manufactured for / Manufactured by” lines (company and site)
  • NDC labeler/applicant listed on the Orange Book
  • any “distributed by” relationships on packaging
  • presentation-specific lot release/manufacturing site references

No such records are included in the input.

Key Takeaways

  • A supplier list for VIRACEPT requires presentation-specific labeling and FDA listing data (NDC, labeler/manufacturer/site).
  • The input does not include VIRACEPT NDC(s), dosage form/strength, or label-manufacturer text, so no accurate named suppliers (API or CMO/CDMO) can be provided without risking errors.

FAQs

  1. Which companies are listed on the VIRACEPT label as “Manufactured by” or “Manufactured for”?
  2. Who produces the nelfinavir mesylate API used for VIRACEPT?
  3. Do VIRACEPT tablets and oral powder come from different manufacturing sites?
  4. How do Orange Book applicant records link to VIRACEPT’s manufacturing entities?
  5. What supplier changes occur when VIRACEPT is sourced through alternate NDC labelers or distributors?

References

No sources are provided in the prompt to cite.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.